Table 3.
Gene silencing against coronaviruses.
| Therapy | Disease | Effect | Ref. |
|---|---|---|---|
| siRNAs | SARS-CoV | Inhibition of replication in Vero E6 cells | [119] |
| SARS-CoV | Prophylactic/therapeutic effects in FRhK4 cells | [120] | |
| SARS-CoV | Suppression of SARS symptoms in primates | [121] | |
| SARS-CoV | Reduced infection in ACE2-silenced cells | [122] | |
| siRNAs, miRNAs | SARS-CoV | Knockdown of ezrin | [123] |
| MERS-CoV | Design of siRNAs, miRNAs for MERS control | [124] | |
| siRNAs | FIPV | siRNA combination delays resistance | [125] |
| shRNAs | PDCoV | Reduced titers and viral RNA in ST cells | [126] |
| PEDV | Inhibition of viral RNA and replication | [127] | |
| SADS-CoV | Inhibition of viral RNA and replication | [127] | |
| PDCoV | Inhibition of viral RNA and replication | [127] |
FIPV, feline infectious peritonitis virus; MERS-CoV, Middle East respiratory syndrome-coronavirus; miRNAs, micro RNAs; PDCoV, porcine deltacoronavirus; PEDV, porcine epidemic diarrhea virus; SADS-CoV, swine acute diarrhea syndrome-coronavirus; SARS-CoV, severe acute respiratory syndrome-coronavirus; shRNAs, short hairpin RNAs; siRNAs, short interfering RNAs; ST, swine testicular.